RBN-3143 is a first-in-class, oral small molecule inhibitor of PARP14.

Ribon Therapeutics dosed the first patient with RBN-3143 in the open-label cohort of patients with moderate-to-severe atopic dermatitis. The study aims to measure the pharmacodynamic activity of RBN-3143 and evaluate the safety and preliminary efficacy of 28 days of administration of RBN-3143 in this target population.

“As a first-in-class, oral, small molecule inhibitor of PARP14, RBN-3143 has the potential to treat a range of inflammatory diseases, including but not limited to atopic dermatitis, asthma and ulcerative colitis. Following the successful completion of the single and multiple ascending dose assessment in healthy subjects to assess safety and pharmacokinetics, we are pleased to be advancing this study into patients with moderate-to-severe atopic dermatitis, the first therapeutic area of focus for the RBN-3143 program,” says Prakash Raman, Ph.D., President and Chief Executive Officer, Ribon Therapeutics, in a news letter. “As a leading company focused on novel targets in the field of cellular stress response, the initiation of the atopic dermatitis portion of our Phase 1 study marks an important advancement in evaluating NAD+-utilizing enzymes as targets for inflammatory diseases.”

“In preclinical models, RBN-3143 suppresses markers of disease, demonstrating its potential as an oral alternative to biologics in a broad range of inflammatory diseases of the skin, lung and the gastrointestinal system,” says Sudha Parasuraman, M.D., Chief Medical Officer, Ribon Therapeutics. “RBN-3143 has demonstrated a favorable safety and pharmacokinetic profile in healthy subjects and we look forward to its evaluation in patients with moderate-to-severe atopic dermatitis and to demonstrate proof-of mechanism.”